secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pacira BioSciences, Inc. (PCRX)
CIK:        0001396814
Form:       8-K
Filed at:   2024-05-07T23:59:59+00:00
Accession:  0001396814-24-000044
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pacira Q1 net income $9.0M ($0.19 EPS); announces $150M share repurchase
------------------------------------------------------------------------

- GAAP net income $9.0M ($0.19/sh) vs net loss $19.5M ($0.43 loss) YoY.
- Total revenue $167.1M, up from $160.3M YoY; EXPAREL net sales $132.4M.
- Adjusted EBITDA $44.6M vs $41.9M YoY; cash flow from ops $49.1M.
- Board authorizes $150M share repurchase program through Dec 2026.
- FY2024 guidance reaffirmed: revenue $680M-$705M, non-GAAP gross margin 74%-76%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1396814/000139681424000044/0001396814-24-000044-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1396814/000139681424000044/pcrx-20240507.htm
  HTML page:      https://secwatch.observer/filing/0001396814-24-000044

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer